Emergent BioSolutions Inc. Quarterly Debt-to-equity in % from Q1 2012 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Emergent BioSolutions Inc. quarterly Debt-to-equity history and growth rate from Q1 2012 to Q2 2024.
  • Emergent BioSolutions Inc. Debt-to-equity for the quarter ending June 30, 2024 was 193 %, a 55.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 193 +68.8 +55.2% Jun 30, 2024
Q1 2024 159 +47.2 +42% Mar 31, 2024
Q4 2023 152 +56.1 +58.3% Dec 31, 2023
Q3 2023 140 +54.4 +63.6% Sep 30, 2023
Q2 2023 125 +42.2 +51.2% Jun 30, 2023
Q1 2023 112 +27.9 +33.1% Mar 31, 2023
Q4 2022 96.1 +8.42 +9.6% Dec 31, 2022
Q3 2022 85.6 -5.99 -6.54% Sep 30, 2022
Q2 2022 82.4 -13.8 -14.3% Jun 30, 2022
Q1 2022 84.4 -16.1 -16% Mar 31, 2022
Q4 2021 87.7 -18.2 -17.2% Dec 31, 2021
Q3 2021 91.6 -18.4 -16.7% Sep 30, 2021
Q2 2021 96.2 -17.6 -15.5% Jun 30, 2021
Q1 2021 100 -20.7 -17.1% Mar 31, 2021
Q4 2020 106 -16.8 -13.7% Dec 31, 2020
Q3 2020 110 -14.8 -11.9% Sep 30, 2020
Q2 2020 114 +14.6 +14.7% Jun 30, 2020
Q1 2020 121 +49.6 +69.3% Mar 31, 2020
Q4 2019 123 +75 +157% Dec 31, 2019
Q3 2019 125 +104 +513% Sep 30, 2019
Q2 2019 99.3 Jun 30, 2019
Q1 2019 71.5 Mar 31, 2019
Q4 2018 47.8 Dec 31, 2018
Q3 2018 20.4 Sep 30, 2018
Q4 2014 70.7 +44.9 +174% Dec 31, 2014
Q3 2014 60.4 +34.8 +136% Sep 30, 2014
Q2 2014 50 +24.8 +98% Jun 30, 2014
Q1 2014 38.1 +12.6 +49.1% Mar 31, 2014
Q4 2013 25.8 -0.18 -0.69% Dec 31, 2013
Q3 2013 25.6 -1.24 -4.61% Sep 30, 2013
Q2 2013 25.3 -3.41 -11.9% Jun 30, 2013
Q1 2013 25.6 -4.37 -14.6% Mar 31, 2013
Q4 2012 26 Dec 31, 2012
Q3 2012 26.9 Sep 30, 2012
Q2 2012 28.7 Jun 30, 2012
Q1 2012 30 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.